Date: June 16, 2026
Board Meeting Outcomes
- The indicative timeline for infusion of funds into Nazara Technologies UK Limited has been extended to August 14, 2026
- This follows the original disclosure dated March 18, 2026 regarding the proposed funding infusion
Disinvestment / Strategic Actions
- Company plans to infuse funds not exceeding USD 100.3 million into Nazara Technologies UK Limited (wholly owned subsidiary)
- Funding to be made in one or more tranches
- Funding structure: USD 40.1 million equity subscription and USD 60.2 million loan
- Subject to compliance with applicable laws
Other Operational / Legal / Strategic Disclosures
No material disclosures under the following sections:
- KMP / Board / Auditor Changes
- Dividend Declaration or Non-Declaration
- Financial Results (Standalone & Consolidated)
- Auditor's Report
- Media Release / Investor Communication